Study with Diamyd Medical’s diabetes vaccine awarded EU-funding

August 27, 2014 Diamyd Medical informs that the ongoing combination study DIABGAD has been awarded EUR 120 000, corresponding to about SEK 1.1 million, in EU-funding. The grant comes from an FP7 project where Linköping University and Diamyd Medical are included. The DIABGAD study aims to evaluate whether vitamin D and ibuprofen act synergistically with the diabetes vaccine Diamyd® in …

Promising data for DNA ‘reverse’ vaccine against Type 1 diabetes

A vaccine designed to combat type-1 diabetes mellitus (T1DM) has delivered promising results in a phase II clinical trial. Researchers at Stanford University School of Medicine trialled the DNA ‘reverse' vaccine in 80 patients with T1DM and taking insulin, and found that in the vaccine group, levels of C-peptide (a proxy of insulin production) were maintained or even occasionally increased …